Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0I0WP
|
|||
Former ID |
DNC009407
|
|||
Drug Name |
4-(methyl(4-phenylthiazol-2-yl)amino)phenol
|
|||
Synonyms |
CHEMBL460515; 4-[Methyl-(4-phenyl-thiazol-2-yl)-amino]-phenol; 4-(methyl(4-phenylthiazol-2-yl)amino)phenol; AC1LDK73; MLS000075845; cid_649391; ZINC813364; HMS2534H13; BDBM50247460; AKOS000563578; SMR000014954; BAS 08769335; SR-01000322128; SR-01000322128-1
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
Structure |
Download2D MOL |
|||
Formula |
C16H14N2OS
|
|||
Canonical SMILES |
CN(C1=CC=C(C=C1)O)C2=NC(=CS2)C3=CC=CC=C3
|
|||
InChI |
1S/C16H14N2OS/c1-18(13-7-9-14(19)10-8-13)16-17-15(11-20-16)12-5-3-2-4-6-12/h2-11,19H,1H3
|
|||
InChIKey |
XDKOSPFALAXPJO-UHFFFAOYSA-N
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Matrix metalloproteinase-13 (MMP-13) | Target Info | Inhibitor | [1] |
NetPath Pathway | IL1 Signaling Pathway | |||
Panther Pathway | Alzheimer disease-presenilin pathway | |||
Plasminogen activating cascade | ||||
Pathway Interaction Database | Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling | |||
Reactome | Collagen degradation | |||
Degradation of the extracellular matrix | ||||
Activation of Matrix Metalloproteinases | ||||
Assembly of collagen fibrils and other multimeric structures | ||||
WikiPathways | Endochondral Ossification | |||
Activation of Matrix Metalloproteinases | ||||
Oncostatin M Signaling Pathway | ||||
AGE/RAGE pathway | ||||
Matrix Metalloproteinases |
References | Top | |||
---|---|---|---|---|
REF 1 | High throughput screening of potentially selective MMP-13 exosite inhibitors utilizing a triple-helical FRET substrate. Bioorg Med Chem. 2009 Feb 1;17(3):990-1005. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.